Standard of care of patients with Chronic Myeloid Leukemia (CML) treated in community based oncology group practices between 2001-2015 in Rhineland- Palatinate (Germany)
Weide, Rudolf; Rendenbach, Bernhard; Grundheber, Monika; Burkhard, Oswald; Behringer, Joachim; Maasberg, Michael; Ehscheidt, Peter; Strehl, John W; Hansen, Richard; Feiten, Stefan.
Appl. cancer res
; 37: 1-8, 2017. tab, ilus
Artículo
en Inglés
| LILACS, Inca | ID: biblio-915148
Background:
The aim of this study was to assess retrospectively treatment and outcome of CML-patients in community based oncology practices in Germany and whether European LeukemiaNET (ELN) recommendations were followed.Method:
All Ph+, BCR-ABL1+ CML-patients who were treated between 11/2001 and 12/2015 in nine oncology group practices were analyzed retrospectively.Results:
Two hundred sixty patients with a median age of 60 (1890) were analyzed. 254 (98%) were in chronic phase, 5 (2%) in accelerated and 1 (0.4%) in blast crisis. 248 patients (95%) received some form of TKI-therapy. 1st line TKI was imatinib in 197 patients (79%), 51 (21%) received a second generation TKI. 75% of TKI-therapies were monitored by PCR. Overall survival after 10 years according to Charlson comorbidity index (CCI) was CCI 2 100%; CCI 34 83%; CCI 56 52%; CCI ≥7 39%. More patients died from comorbidities (8%) than from CML (5%). Whether patients died was strongly correlated to CCI at diagnosis CCI 2 3% of patients died, CCI 34 16% of patients died, CCI 56 38% of patients died, CCI ≥ 7 42% of patients died.Conclusion:
CML-patients treated in oncology group practices receive standard of care as recommended by ELN. Overall survival in routine care is comparable to international studies. Molecular monitoring should be improved (AU)
Biblioteca responsable:
BR30.1
Texto completo
Documentos relacionados